Skip to main content

Table 2 Meta-analysis of the HIF-1α C1772T polymorphism and cancer risk

From: Association between HIF-1α C1772T/G1790A polymorphisms and cancer susceptibility: an updated systematic review and meta-analysis based on 40 case-control studies

Variables    TT vs.CC CT vs.CC CT + TT vs.CC TT vs.CT + CC T vs.C
Study Case/control I 2 Phet OR (95% CI) Case/control I 2 Phet OR (95% CI) Case/control I 2 Phet OR (95% CI) case/control I 2 Phet OR (95% CI) Case/control I 2 Phet OR (95% CI)
Overall 40 9301/12392 67 <0.001 1.63 (1.02-2.60)* 10562/14078 68 <0.001 1.08 (0.92-1.26)* 10958/14676 70 <0.001 1.15 (1.01-1.34)* 10540/12470 71 <0.001 2.11 (1.32-3.37)* 21738/28578 76 <0.001 1.21 (1.04-1.41)*
Overall in HWE 31 7429/9947 59 0.02 2.21 (1.27-3.83)* 8481/11109 64 <0.001 1.15 (0.98-1.36)* 8604/11556 70 <0.001 1.20 (1.02-1.41)* 8275/9350 49 0.01 2.13 (1.28-3.55)* 17208/22338 76 <0.001 1.22 (1.03-1.44)*
Cancer type
Cervical 3 664/750 66 0.09 10.11 (2.55-40.05) 739/871 60 0.08 0.98 (0.72-1.34) 749/874 80 0.01 1.32 (0.61-2.87)* 749/874 51 0.15 8.55 (2.28-32.13) 2369/1748 88 <0.001 1.41 (0.59-3.35)*
Breast 6 1859/1809 62 0.03 1.41 (0.34-5.75)* 2117/2033 37 0.16 1.01 (0.91-1.33) 2143/2046 46 0.1 1.13 (0.94-1.36) 2143/2046 60 0.04 1.38 (0.35-5.46)* 4286/4092 56 0.04 1.09 (0.80-1.48)*
Breast in HWE 5 1784/1744 55 0.08 2.30 (1.08-4.91) 2022/1963 35 0.19 1.07 (0.88-1.29) 2047/1972 56 0.06 1.12 (0.92-1.35) 2047/1972 49 0.12 2.27 (1.06-4.82) 4154/3944 65 0.02 1.09 (0.76-1.55)*
Breast in Asian 3 1605/1564 0 0.93 4.42 (1.60-12.21) 1809/1742 36 0.21 1.14 (0.92-1.41) 1832/1746 51 0.13 1.22 (0.99-1.49) 1832/1746 0 0.91 4.16 (1.51-11.48) 3664/3492 55 0.11 1.28 (1.05-1.55)
Lung 3 375/438 75 0.04 1.41 (0.07-30.44)* 471/553 75 0.02 1.13 (0.59-2.19)* 509/566 86 0.01 1.19 (0.51-2.76)* 509/566 71 0.07 3.27 (1.73-6.17) 1018/1132 89 <0.001 1.19 (0.50-2.86)*
Colorectal 4 599/2123 - - - 624/2175 79 0.03 0.24 (0.01-5.51)* 627/2177 71 0.02 1.12 (0.57-2.18)* 627/2177 - - - 1254/4354 80 0.02 0.26 (0.01-6.38)*
Prostate 6 3149/3415 70 0.01 1.34 (0.54-3.31)* 3766/4032 86 <0.001 1.34 (0.93-1.92)* 3816/4084 87 <0.001 1.36 (0.95-1.96)* 3816/4084 69 0.01 1.31 (0.54-3.20)* 7632/8168 87 <0.001 1.35 (0.96-1.89)*
Prostate in HWE 4 1814/2067 59 0.09 1.57 (0.89-2.75) 2168/2417 88 <0.001 1.42 (0.84-2.40)* 2200/2438 87 0.01 1.50 (0.89-2.40)* 2200/2438 61 0.08 1.55 (0.89-2.72) 4400/4876 85 <0.001 1.44 (0.93-2.21)*
Renal 4 1015/1035 25 0.26 0.28 (0.12-1.28) 1065/1157 74 0.01 0.62 (0.31-1.24)* 1160/1241 70 0.02 0.62 (0.33-1.18)* 1160/1241 21 0.29 1.37 (0.92-2.04) 2320/2482 44 0.15 0.91 (0.73-1.12)
Renal in HWE 2 867/847 0 0.62 0.67 (0.21-2.13) 947/929 13 0.28 0.92 (0.67-1.26) 952/936 29 0.24 0.90 (0.67-1.22) 952/936 0 0.64 0.69 (0.22-2.17) 1904/1872 37 0.21 0.89 (0.67-1.19)
Oral 4 549/547 0 0.46 2.01 (0.75-5.41) 542/668 50 0.14 0.90 (0.55-1.47) 589/679 16 0.3 1.04 (0.66-1.64) 589/679 93 <0.001 22.82 (0.28-1887.72)* 1178/1358 88 <0.001 2.52 (0.71-8.98)*
Oral in HWE 2 446/423 - - - 478/443 0 0.5 1.28 (0.69-2.38) 479/443 0 0.4 1.35 (0.73-2.49) 479/443 - - - 958/886 0 0.32 1.41 (0.78-2.56)
Other 12 1033/2151 30 0.2 3.18 (1.90-5.32) 1190/2445 67 <0.001 1.18 (0.79-1.78)* 1276/2622 60 <0.001 1.34 (0.95-1.87)* 1276/2622 0 0.52 3.31 (1.98-5.53) 2434/4940 58 0.01 1.47 (1.10-1.96)*
Other in HWE 9 880/1032 56 0.08 5.10 (1.72-15.07) 1032/1758 60 0.01 1.47 (0.97-2.21)* 1041/1763 64 0.01 1.52 (0.99-2.34)* 1041/1763 24 0.27 4.47 (1.53-13.00) 2082/3526 67 0.01 1.52 (1.02-2.28)*
Ethnicity
Asian 20 5124/5781 0 0.96 4.10 (2.49-6.76) 5678/6335 50 0.01 1.20 (0.99-1.46)* 5787/6400 75 <0.001 1.29 (1.04-1.58)* 5787/6400 0 0.98 3.67 (2.23-6.02) 11574/12800 61 <0.001 1.28 (1.04-1.57)
Caucasian 16 1791/4247 74 <0.001 1.54 (0.72-3.27)* 2220/4781 76 <0.001 0.93 (0.65-1.33)* 2385/4921 59 0.01 1.07 (0.80-1.43)* 2385/4921 58 0.003 1.95 (1.14-3.31)* 4770/9842 78 <0.001 1.20 (0.91-1.57)
Caucasian in HWE 9 1473/3153 76 <0.001 2.28 (0.62-8.35)* 1738/3152 79 <0.001 1.20 (0.99-1.46)* 1776/3535 82 <0.001 1.28 (0.88-1.86)* 1776/3535 69 0.002 2.08 (0.68-6.37)* 3552/7070 86 <0.001 1.34 (0.86-2.07)
Source of control
HB 17 4608/5249 77 <0.001 3.28 (1.29-8.30)* 5259/6029 60 <0.001 1.18 (0.96-1.45)* 5348/6086 72 <0.001 1.28 (1.01-1.62)* 5348/6086 71 <0.001 2.85 (1.24-6.54)* 10696/12172 80 <0.001 1.33 (1.04-1.71)*
HB in HWE 15 3340/3962 35 0.13 4.88 (2.96-8.04) 3748/4467 56 0.01 1.24 (0.99-1.57)* 3810/4488 67 <0.001 1.33 (1.02-1.74)* 3810/4488 4 0.4 4.23 (2.58-6.93) 7620/8976 74 <0.001 1.38 (1.06-1.80)*
PB 23 4693/5303 54 0.01 1.33 (0.76-2.31)* 5303/7143 74 <0.001 0.99 (0.77-1.29)* 5521/8203 70 <0.001 1.10 (0.89-1.36)* 5521/8203 72 <0.001 2.02 (1.10-3.71)* 11042/16406 74 <0.001 1.18 (0.95-1.45)*
PB in HWE 15 4089/5985 49 0.04 1.51 (0.74-3.11)* 4733/6642 72 <0.001 1.10 (0.85-1.43)* 4794/6681 72 <0.001 1.17 (0.93-1.48)* 4794/6681 46 0.63 1.51 (1.01-2.27) 9588/13362 75 <0.001 1.14 (0.89-1.45)*
  1. HWE: Hardy-Weinberg Equilibrium; PB: population based; HB: hospital based; Phet: P value for heterogeneity. *Random-effects model was used when P value for heterogeneity test <0.05; otherwise, fixed-effects model was used.